Journal Logo

Articles by D. el Fassi

THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: S1609

Knudsen, T. A.; Hansen, Lund D.; Ocias, Frans L.; More

HemaSphere. 3:741-742, June 2019.

IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL: PB2210

Patel, D.; Knudsen, Alma T.; Hansen, Lund D.; More

HemaSphere. 3:990-991, June 2019.